CCI Clears Pharma Associations After Detailed Review, Dispelling Concerns Over Mandatory NOCs and PIS Charges in Drug Distribution

CCI Clears Pharma Associations After Detailed Review, Dispelling Concerns Over Mandatory NOCs and PIS Charges in Drug Distribution​

The Competition Commission of India (CCI) has issued a landmark ruling concluding that no anti-competitive contraventions were established against the various associations and pharmaceutical companies previously investigated. The decision brings definitive clarity to the landscape of drug distribution, finding that the mandatory nature of certain regulatory practices—such as obtaining No Objection Certificates (NOCs) for stockist appointments or compulsory PIS approvals for new product launches—was not conclusively proven after subsequent industry compliance measures were undertaken.

The case, which centered on allegations of concerted and conspiratorial refusal to deal within the pharmaceutical sector, has concluded following a thorough examination of the Director General’s investigation report (DGIR). The CCI's order signals a reduction in regulatory uncertainty for manufacturers and distributors operating under the framework of industry associations.

Anti-Competitive Allegations Against Pharma Ecosystem​

The case examined allegations dating back to the early 2000s, which suggested that organized sector bodies held undue influence over market operations. The primary concerns raised by the informant body, All India Chemist and Distributors Federation (AICDF), related to three key areas of alleged coercive practices: mandatory NOC/LOC requirements for appointing distributors or wholesalers, compulsory Product Information Service (PIS) approvals before launching new drugs, and imposed trade margins set through agreements between industry bodies.

Multiple associations and pharmaceutical manufacturers were named as Opposite Parties (OPs). These included prominent entities such as All India Organisation of Chemist & Druggist (OP-1), Indian Drug Manufacturers' Association (IDMA/OP-2), and the Organisation of Pharmaceutical Producers of India (OPPI/OP-3). The investigations also covered nearly two dozen pharmaceutical companies, ranging from Glaxo SmithKline to Sun Pharma.

Investigation Findings and Industry Defense​

The investigation report by the DG had concluded that practices like mandating NOCs or requiring PIS approval constituted limiting and controlling supply in the market, leading to contravention of Section 3(3)(b) of the Competition Act by several associated bodies. The reports alleged that these restrictions continued despite a Memorandum of Understanding (MoU) between OP-1, OP-2, and OP-3 having been terminated in 2011.

In response, the pharmaceutical companies challenged the findings extensively. Companies argued that they were operating in a coercive environment created by associations. Several submitted that their stockist appointments and trade margin decisions were matters of independent commercial decision-making, not compulsion dictated by any association. Opponents stressed that conduct arising from coercion could not be deemed an agreement under the Act.

CCI Rules Finds No Evidence of Mandatory Control Post-2014​

The Commission meticulously reviewed all evidence, including submissions made by various manufacturers and associations. The pivotal finding established was that the initial DG's conclusions—that practices like mandatory NOCs or compulsory PIS approvals were uniformly enforced—were not conclusively proven based on the available material.

Specifically, the CCI noted that OP-1 had filed an Affidavit of Compliance in 2014, categorically affirming that practices relating to NOC/LOC requirements and collection of PIS charges were discontinued. The Commission observed that subsequent compliance undertakings and communications from associations explicitly clarified that these services were entirely voluntary, not mandatory.

The ruling states that the material available on record does not conclusively establish that appointment of stockists was dependent upon obtaining NOCs/LOCs or that pharmaceutical companies were prevented from launching products in the absence of PIS approvals after April 3, 2014. This conclusion means the findings against certain associations for violating Section 3(3)(b) cannot be sustained.

Implications and Conclusion on Market Practice​

The CCI’s decision reaffirms that while industry associations play a vital role in setting standards and facilitating product dissemination, their activities must not cross into mandatory control or coercion over manufacturers. The ruling underscores the importance of voluntary conduct within the market.

Furthermore, the Commission addressed the issue of individual liability under Section 48 of the Act. Given that none of the OPs were found to be in contravention of Section 3 of the Act, the CCI determined that the question of examining the liability of their office bearers or associated individuals does not arise in these facts and circumstances, closing the proceedings against them as well.